Results 91 to 100 of about 16,213 (203)

Reworking the treatment of Indian Post kala-azar dermal leishmaniasis: A two-step therapy

Journal of Vector Borne Diseases
In the current scenario, treatment of Post kala-azar dermal leishmaniasis (PKDL) is intravenous liposomal amphotericin B or oral miltefosine. Over the years, there has been a gradual decline in the efficacy of miltefosine and a rise in permanent loss of ...
Sushruta Kathuria, Yugansh Gautam, Niti Khunger, Shruti Sharma, Ruchi Singh   +4 more
doaj   +1 more source

Hyperphosphatemia in Pediatric Oncology Patients Receiving Liposomal Amphotericin B

, 2011
OBJECTIVE: After transitioning our front-line amphotericin product to the liposomal formulation, we observed an increased incidence of hyperphosphatemia.
Knoderer, Holly M., Knoderer, Chad A.
core   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Clearance of Fungal Burden during Treatment of Disseminated Histoplasmosis with Liposomal Amphotericin B versus Itraconazole

, 2001
Animal studies have shown that fungal burden correlates with survival during treatment with new antifungal therapies for histoplasmosis. The purpose of this report is to compare the clearance of fungal burden in patients with histoplasmosis treated with ...
Philip C. Johnson, Ann Le Monte, Deanna E. Fuller, Gretchen Cloud, null null, L. Joseph Wheat, Patricia Connolly, Mitchell Goldman, Richard Hafner, Thomas E. Davis   +9 more
core   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

ENDEMIC MYCOSES PROGRAM IN THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS): CASE CHARACTERIZATION AND PHARMACOECONOMIC IMPACT IN A HIGH-COMPLEXITY UNIVERSITY HOSPITAL

Brazilian Journal of Infectious Diseases
Introduction/Objectives: The Ministry of Health Endemic Mycoses Program is essential in SUS, ensuring access to high-cost antifungals for patients with systemic fungal infections, according to RENAME and Clinical Protocols and Therapeutic Guidelines ...
Andressa Barros, Gilian Batista Balbueno Guerreiro, Maitê Roxo dos Santos, Lucia Collares Meirelles   +3 more
doaj   +1 more source

Amphotericin-B/amphotericin-B-liposomal [PDF]

Reactions Weekly, 2022
openaire   +1 more source

Pharmacokinetics of liposomal amphotericin B in pleural fluid.

, 2010
We report the penetration of liposomal amphotericin B into the pleural fluid of a patient with pulmonary zygomycosis and empyema. The ratio of area under the concentration-versus-time curve in pleural fluid (AUC(pleural fluid)) to that in serum (AUC ...
Roy Chowdhuri, Sinchita, Pratt, Alexandra K, Pennick, Gennethel, Henning, Stacey A, Moriyama, Brad, Shea, Yvonne R, Rinaldi, Michael G, Barrett, A John, Torabi-Parizi, Parizad, Walsh, Thomas J   +9 more
core  

Proportion of patients achieving initial and definitive cure after treatment with amphotericin B emulsion and liposomal amphotericin B (mITT population).

, 2014
Data are n (%); mITT = modified Intent-to-Treat; CI = confidence interval.Proportion of patients achieving initial and definitive cure after treatment with amphotericin B emulsion and liposomal amphotericin B (mITT population).
Tara Kant Jha (631050), Shyam Sundar (58354), Chandra Shekhar Lal (631051), Deepak Verma (631052), Neena Verma (505159), Chandreshwar Prasad Thakur (631049), Pradeep Das (230639), Vidya Nand Ravi Das (567509), Shahnawaz Alam (631053), Krishna Pandey (567511)   +9 more
core   +1 more source

Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion.

, 2014
Liposomal amphotericin-B (AmBisome) is now becoming first choice for the treatment of visceral leishmaniasis (kala-azar) patients due to high efficacy and less toxicity.
Noiri, E, Basher, A, Maude, RJ, Nath, P, Faiz, A, Sarkar, S, Selim, S, Harada, M   +7 more
core   +1 more source